SPXA yields 20408.16% · ABBV yields 3.06%● Live data
📍 SPXA pulled ahead of the other in Year 1
Combined, SPXA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SPXA + ABBV for your $10,000?
Spectrum DNA, Inc. operates a social media studio that creates digital networked applications, which are engines of engagement (enginets) primarily for media outlets and brand advertisers. Its enginets are branded Web and wireless-based network experiences, and Web and mobile applications. The company's principal enginets include The Addictionary, a social wordplay engine used as the foundation for apps created to engage in word-related apps; and PlanetTagger, a location-enabled integrated social marketing platform that offers online communities a tool, which centralize the social media marketing and editorial programming, as well as provides the community users with utility to extend the reach of the community. It also offers OptEngage, a new class configurable and contextual browser application that talks to a cloud-based platform, which enables clients to deliver content and utility to their users on the Web; and the Hucklemonkey, an application programming interface API that integrates gamification into clients existing services or new applications. The company was founded in 2006 and is based in Park City, Utah.
Full SPXA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.